Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-70
SponsorMansoura University Hospital
About this trial
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.
The presence of non-fully reversible airflow obstruction (FEV1/FVC \< 0.7 post-bronchodilation) measured by spirometry confirms the diagnosis of COPD
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria
Disqualifiers
Patients with known allergic diseases before enrollment
Patients with associated other chronic respiratory disorders
Patients with significant comorbidities that could influence respiratory function.
Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment.
Trial population
Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria
Trial design
Design model
Case-crossover
Time perspective
Prospective
Treatments tested in this trial
Skin prick test
Diagnostic testSkin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold. Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Chronic obstructive pulmonary disease patients1 intervention
Trial outcomes
Primary outcomes
1
Atopy in chronic obstructive pulmonary disease patients
Total IgE (mg/dl) and ) will be assessed in chronic obstructive pulmonary disease patients
Time frame
6 months2
Chronic obstructive pulmonary disease patients
Blood eosinophil count (%) will be assessed in chronic obstructive pulmonary disease patients
Time frame
2 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov